Building Momentum in Precision Oncology Across Latin America​

  • News
At the 1st Symposium on Genomics and Precision Oncology in Brazil (April 10–11), over 300 oncologists gathered to advance the future of cancer care and the Gene Solutions Brazil team was proud to contribute.​
  
A major standout was the insightful session on “Liquid Biopsy: Detection of ctDNA and Minimal Residual Disease (MRD)” led by Dr. Raphael Brandão, Chief of Oncology at São Camilo Hospital.​
Dr. Brandão explored how liquid biopsy is shifting from concept to standard of care, offering:​
– Real-time ctDNA monitoring of treatment response, enabling earlier identification of disease progression and timely detection of relapse​.
– Data-driven ctDNA-guided treatment decision-making, informed by individual genomic profiles and patient-specific molecular signatures​.
– Minimally invasive testing that prioritizes patient comfort and improves adherence​.
Missed the event? This marks a strong start for precision oncology in LATAM. More scientific sessions and collaborative activities are coming – stay tuned.​
Take a closer look at how our AI-enhanced multi-omics solutions are advancing earlier cancer detection with SPOT-MAS, comprehensive genomic profiling and ctDNA-monitoring with K-TRACK and K-4CARE to optimize cancer care:​
Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More